Replies to post #6278 on Insmed Inc (INSM)

[surf1944]

4:38PM Insmed to report top-line results from Phase 3 clinical trial of ARIKACE to treat pseudomonas aeruginosa in cystic fibrosis on Monday, July 1 (INSM) 11.96 +0.22 : Co announced that it will report top-line results from its European and Canadian Phase 3 study of ARIKACE (liposomal amikacin for inhalation) to treat cystic fibrosis patients with Pseudomonas aeruginosa lung infections on Monday, July 1, 2013 at 7:00 a.m. Eastern time. Insmed management will hold a conference call to discuss the results and answer questions on Monday, July 1, 2013 beginning at 8:00 a.m. Eastern time.